Orifarm
Orifarm, officially known as Orifarm Group, is a prominent player in the pharmaceutical industry, headquartered in Denmark (DK). Founded in 1994, the company has established itself as a leader in the development, production, and distribution of generic medicines and parallel imports, primarily serving the European market. With a strong focus on quality and accessibility, Orifarm offers a diverse portfolio of products, including prescription medications and over-the-counter solutions. Their commitment to innovation and sustainability sets them apart in a competitive landscape. Over the years, Orifarm has achieved significant milestones, including expanding its operational reach across multiple European countries. The company is recognised for its dedication to improving patient access to essential medicines, solidifying its position as a trusted partner in the healthcare sector.
DitchCarbon Score
How does Orifarm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Orifarm's score of 28 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Orifarm's reported carbon emissions
In 2023, Orifarm reported total carbon emissions of approximately 11,949,000 kg CO2e, comprising 4,420,000 kg CO2e from Scope 1 and 7,529,000 kg CO2e from Scope 2 emissions. This marks a slight decrease from 2022, where total emissions were about 12,579,000 kg CO2e, with Scope 1 emissions at 4,315,000 kg CO2e and Scope 2 emissions at 8,264,000 kg CO2e. Orifarm has committed to achieving net-zero emissions across all scopes by 2050, as part of its long-term climate strategy. This commitment aligns with the Science Based Targets initiative (SBTi), which Orifarm joined in 2023. The company is actively working towards reducing its carbon footprint and has set interim targets to guide its progress. Overall, Orifarm's emissions data reflects its ongoing efforts to address climate change within the pharmaceutical sector, demonstrating a commitment to sustainability and responsible environmental stewardship from its headquarters in Denmark (DK).
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 732,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 575,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orifarm is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
